Anatomical Distribution of Cuprizone-Induced Lesions in C57BL6 Mice

Journal of Molecular Neuroscience

Volumn 57, Issue 2, 2015, Pages 166-175

  Goldberg, Johannes ^a   Clarner, Tim ^a   Beyer, Cordian ^a   Kipp, Markus ^b,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Anatomische Anstalt   (Germany)

Author keywords

Axonal damage; Cuprizone; Demyelination; Gray matter; Microglia; Neurodegeneration; White matter

Indexed keywords

CUPRIZONE; MONOAMINE OXIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR COMMISSURE; ARTICLE; BRAIN LEVEL; CAPSULA INTERNA; CINGULUM (BRAIN); CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; FOREBRAIN; GLIOSIS; GLOBUS PALLIDUS; GRAY MATTER; HIPPOCAMPAL FIMBRIA; MALE; MICROGLIA; MOUSE; NONHUMAN; STRIA TERMINALIS; SUBSTANTIA INNOMINATA; SUBTHALAMIC NUCLEUS; WHITE MATTER; ZONA INCERTA; ANIMAL; AXON; C57BL MOUSE; CHEMICALLY INDUCED; DEMYELINATING DISEASE; MYELIN SHEATH; PATHOLOGY;

ANIMALS; AXONS; CORPUS CALLOSUM; CUPRIZONE; DEMYELINATING DISEASES; GRAY MATTER; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; MYELIN SHEATH; WHITE MATTER;

EID: 84942197205     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-015-0595-5     Document Type: Article

References (42)

1. Acs P, Kalman B (2012) Pathogenesis of multiple sclerosis: what can we learn from the cuprizone model. Methods Mol Biol 900:403–431
2. Acs P, Kipp M, Norkute A, Johann S, Clarner T, Braun A, Berente Z, Komoly S, Beyer C (2009) 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 57:807–814
3. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W (2000) Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123(Pt 6):1174–1183
4. Blakemore WF (1972) Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J Neurocytol 1:413–426
5. Blakemore WF, Franklin RJ (2008) Remyelination in experimental models of toxin-induced demyelination. Curr Top Microbiol Immunol 318:193–212
6. Buschmann JP, Berger K, Awad H, Clarner T, Beyer C, Kipp M (2012) Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. J Mol Neurosci 48:66–76
7. Carlton WW (1966) Response of mice to the chelating agents sodium diethyldithiocarbamate, alpha-benzoinoxime, and biscyclohexanone oxaldihydrazone. Toxicol Appl Pharmacol 8:512–521
8. Clarner T, Janssen K, Nellessen L, Stangel M, Skripuletz T, Krauspe B, Hess FM, Denecke B, Beutner C, Linnartz-Gerlach B, Neumann H, Vallieres L, Amor S, Ohl K, Tenbrock K, Beyer C, Kipp M (2015) CXCL10 triggers early microglial activation in the cuprizone model. J Immunol 194:3400–3413
9. Goldberg J, Daniel M, van Heuvel Y, Victor M, Beyer C, Clarner T, Kipp M (2013) Short-term cuprizone feeding induces selective amino acid deprivation with concomitant activation of an integrated stress response in oligodendrocytes. Cell Mol Neurobiol 33:1087–1098
10. Groebe A, Clarner T, Baumgartner W, Dang J, Beyer C, Kipp M (2009) Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 8:163–174
11. Gudi V, Moharregh-Khiabani D, Skripuletz T, Koutsoudaki PN, Kotsiari A, Skuljec J, Trebst C, Stangel M (2009) Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res 1283:127–138
12. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357:851–862
13. Herder V, Hansmann F, Stangel M, Skripuletz T, Baumgartner W, Beineke A (2011) Lack of cuprizone-induced demyelination in the murine spinal cord despite oligodendroglial alterations substantiates the concept of site-specific susceptibilities of the central nervous system. Neuropathol Appl Neurobiol 37:676–684
14. Herrero-Herranz E, Pardo LA, Gold R, Linker RA (2008) Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis 30:162–173
15. Hiremath MM, Chen VS, Suzuki K, Ting JP, Matsushima GK (2008) MHC class II exacerbates demyelination in vivo independently of T cells. J Neuroimmunol 203:23–32
16. Hoffmann K, Lindner M, Groticke I, Stangel M, Loscher W (2008) Epileptic seizures and hippocampal damage after cuprizone-induced demyelination in C57BL/6 mice. Exp Neurol 210:308–321
17. Kang Z, Liu L, Spangler R, Spear C, Wang C, Gulen MF, Veenstra M, Ouyang W, Ransohoff RM, Li X (2012) IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination. J Neurosci 32:8284–8292
18. Kipp M, Norkute A, Johann S, Lorenz L, Braun A, Hieble A, Gingele S, Pott F, Richter J, Beyer C (2008) Brain-region-specific astroglial responses in vitro after LPS exposure. J Mol Neurosci 35:235–243
19. Kipp M, Clarner T, Dang J, Copray S, Beyer C (2009) The cuprizone animal model: new insights into an old story. Acta Neuropathol 118:723–736
20. Kipp M, Norkus A, Krauspe B, Clarner T, Berger K, van der Valk P, Amor S, Beyer C (2011) The hippocampal fimbria of cuprizone-treated animals as a structure for studying neuroprotection in multiple sclerosis. Inflamm Res 60:723–726
21. Kipp M, van der Star B, Vogel DY, Puentes F, van der Valk P, Baker D, Amor S (2012a) Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Mult Sclera Relat Disorder 1:15–28
22. Kipp M, van der Valk P, Amor S (2012b) Pathology of multiple sclerosis. CNS Neurol Disord Drug Targets 11:506–517
23. Krauspe BM, Dreher W, Beyer C, Baumgartner W, Denecke B, Janssen K, Langhans CD, Clarner T, Kipp M (2015) Short-term cuprizone feeding verifies N-acetylaspartate quantification as a marker of neurodegeneration. J Mol Neurosci 55:733–748
24. Krone B, Oeffner F, Grange JM (2009) Is the risk of multiple sclerosis related to the 'biography' of the immune system? J Neurol 256:1052–1060
25. Linares D, Taconis M, Mana P, Correcha M, Fordham S, Staykova M, Willenborg DO (2006) Neuronal nitric oxide synthase plays a key role in CNS demyelination. J Neurosci 26:12672–12681
26. Norkute A, Hieble A, Braun A, Johann S, Clarner T, Baumgartner W, Beyer C, Kipp M (2009) Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J Neurosci Res 87:1343–1355
27. Pasquini LA, Calatayud CA, Bertone Una AL, Millet V, Pasquini JM, Soto EF (2007) The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia. Neurochem Res 32:279–292
28. Pott F, Gingele S, Clarner T, Dang J, Baumgartner W, Beyer C, Kipp M (2009) Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia. Brain Res 1305:137–149
29. Ramagopalan SV, Ebers GC (2008) Genes for multiple sclerosis. Lancet 371:283–285
30. Remington LT, Babcock AA, Zehntner SP, Owens T (2007) Microglial recruitment, activation, and proliferation in response to primary demyelination. Am J Pathol 170:1713–1724
31. Simpson S Jr, Taylor BV, van der Mei I (2015) The role of epidemiology in MS research: past successes, current challenges and future potential. Mult Scler
32. Skripuletz T, Lindner M, Kotsiari A, Garde N, Fokuhl J, Linsmeier F, Trebst C, Stangel M (2008) Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 172:1053–1061
33. Skripuletz T, Bussmann JH, Gudi V, Koutsoudaki PN, Pul R, Moharregh-Khiabani D, Lindner M, Stangel M (2010) Cerebellar cortical demyelination in the murine cuprizone model. Brain Pathol 20:301–312
34. Skripuletz T, Gudi V, Hackstette D, Stangel M (2011a) De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol Histopathol 26:1585–1597
35. Skripuletz T, Miller E, Grote L, Gudi V, Pul R, Voss E, Skuljec J, Moharregh-Khiabani D, Trebst C, Stangel M (2011b) Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system. Brain Behav Immun 25:1592–1606
36. Skripuletz T, Hackstette D, Bauer K, Gudi V, Pul R, Voss E, Berger K, Kipp M, Baumgartner W, Stangel M (2013) Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 136:147–167
37. Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJ (2003) Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol 13:329–339
38. van der Star BJ, Vogel DY, Kipp M, Puentes F, Baker D, Amor S (2012) In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets 11:570–588
39. van der Valk P, Amor S (2009) Preactive lesions in multiple sclerosis. Curr Opin Neurol 22:207–213
40. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, Li X, Dyck LE, Devon RM, Deng Y, Li XM (2008) Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 13:697–708
41. Yang HJ, Wang H, Zhang Y, Xiao L, Clough RW, Browning R, Li XM, Xu H (2009) Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: implications for the pathophysiology of schizophrenia. Brain Res 1270:121–130
42. Zendedel A, Beyer C, Kipp M (2013) Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci 51:567–572